Prophylactic treatment in severe hemophilia is very effective but is limited by cost issues. The implementation of 2 different prophylactic regimens in The Netherlands and Sweden since the 1970s may be considered a natural experiment. We compared the costs and outcomes of Dutch intermediate- and Swedish high-dose prophylactic regimens for patients with severe hemophilia (factor VIII/IX 10 of 144 points in 46% vs 11% of participants), although social participation and quality of life were similar. Annual total costs were 66% higher for high-dose prophylaxis (mean, 180 [95% confidence interval, 163 - 196] × US$1000 for Dutch vs 298 [95% confidence interval, 271-325]) × US$1000 for Swedish patients; (P
Notes
Cites: Haemophilia. 2001 Sep;7(5):446-5211554930
Cites: Qual Life Res. 2001;10(7):621-3511822795
Cites: Blood. 2002 Apr 1;99(7):2337-4111895765
Cites: Haemophilia. 2002 Nov;8(6):753-6012410643
Cites: Med Sci Sports Exerc. 2003 Aug;35(8):1381-9512900694
